Luke Miels
Vorstandsvorsitzender bei
GSK PLC
Vermögen: 11 Mio $ am 31.07.2026
Profil
Luke Victor Miels is currently Chief Executive Officer & Executive Director at GSK Plc since 2026, Director at ViiV Healthcare Co., and Member of the Singapore Economic Development Board.
Former roles include Executive VP-Global Portfolio & Product Strategy at AstraZeneca PLC and Regional VP-Asia Pacific & Pharmaceuticals Division at Roche Pharmaceuticals, Inc. Education includes an MBA from Macquarie University and undergraduate studies at Flinders University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GSK PLC 0,01 % | 10.07.2026 | 413.119 ( 0,01 % ) | 11 Mio $ | 31.07.2026 |
Aktuelle Nachrichten zu Luke Miels
Aktive Positionen von Luke Miels
| Unternehmen | Position | Beginn |
|---|---|---|
| GSK PLC | Vorstandsvorsitzender | 01.01.2026 |
ViiV Healthcare Co.
 ViiV Healthcare Co. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, ViiV Healthcare is a pharmaceutical company that specializes in HIV medicines and research, with a focus on people living with HIV and AIDS. The company is based in Raleigh, NC. The company is committed to finding new ways to treat, prevent, and ultimately find a cure for HIV, while also focusing on bridging the gap between research and clinical practice through implementation science and patient-centered studies. ViiV Healthcare takes a holistic approach to developing new medicines and supporting sustainable community programs for the HIV community. The company's scientists have been at the forefront of developing innovative HIV medicines since the start of the HIV and AIDS epidemic. ViiV Exchange is a platform that provides healthcare professionals with access to product information, clinical data, publications, webcasts, and medical education related to HIV. The company is dedicated to treating, preventing, and eventually curing HIV. | Direktor/Vorstandsmitglied | - |
Singapore Economic Development Board
 Singapore Economic Development Board General GovernmentGovernment Provides plans and excutives ecomomic strategies | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Luke Miels
| Unternehmen | Position | Ende |
|---|---|---|
| ASTRAZENECA PLC | Corporate Officer/Principal | 01.01.2017 |
Roche Pharmaceuticals, Inc.
 Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development services | Corporate Officer/Principal | - |
Ausbildung von Luke Miels
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
84
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development services | Commercial Services |
GSK Plc
 GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
Singapore Economic Development Board
Singapore Economic Development Board General GovernmentGovernment Provides plans and excutives ecomomic strategies | Government |
Macquarie University
 Macquarie University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Flinders University
 Flinders University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ViiV Healthcare Co.
ViiV Healthcare Co. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, ViiV Healthcare is a pharmaceutical company that specializes in HIV medicines and research, with a focus on people living with HIV and AIDS. The company is based in Raleigh, NC. The company is committed to finding new ways to treat, prevent, and ultimately find a cure for HIV, while also focusing on bridging the gap between research and clinical practice through implementation science and patient-centered studies. ViiV Healthcare takes a holistic approach to developing new medicines and supporting sustainable community programs for the HIV community. The company's scientists have been at the forefront of developing innovative HIV medicines since the start of the HIV and AIDS epidemic. ViiV Exchange is a platform that provides healthcare professionals with access to product information, clinical data, publications, webcasts, and medical education related to HIV. The company is dedicated to treating, preventing, and eventually curing HIV. | Health Technology |
